0001213900-22-066882 | 20-F | XBRL Viewer

$ 1,897,596

$ 604,884

Segment Information (Details) - Schedule of revenue and expenses for the period and assets and liabilities [Line Items]

(14,903,909)

(11,372,799)

(4,697,636)

Consolidated [Member]

1,897,596

6,271

2,679

782,383

73,069

(15,692,563)

(13,346,143)

(14,903,909)

(11,372,799)

37,879,608

9,328,795

Psychedelic products [Member]

(2,010,533)

(755,049)

Segment Information (Details) - Schedule of revenue and expenses for the period and assets and liabilities [Line Items]

(883,708)

(768,316)

(883,708)

(768,316)

56,058

2,000

Cannabinoid Products [Member]

(354,310)

Segment Information (Details) - Schedule of revenue and expenses for the period and assets and liabilities [Line Items]

1,897,596

^[1]

782,383

(4,642,796)

(5,202,371)

(3,860,317)

(3,304,769)

263,731

104,267

Segment Information (Details) - Schedule of revenue and expenses for the period and assets and liabilities [Line Items]

(577,819)

(86,522)

Corporate [Member]

6,175

2,673

73,069

(10,166,059)

(7,375,456)

(10,159,884)

(7,299,714)

37,559,819

9,222,528

Schedule Of Ordinary Shares Movements During Years Abstract

$ (1,078,404)

$ (668,527)

[1]	Of the total revenue from pharmaceuticals in each year, 100% was through Cannvalate Pty Ltd’s distribution network.

Income tax (Details) - Schedule of income tax benefit on pre-tax accounting loss from operations reconciles to the inco - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Income Tax Benefit On Pre Tax Accounting Loss From Operations Reconciles To The Inco Abstract
Accounting loss before tax	$ (14,903,909)	$ (11,372,799)	$ (4,697,636)
Income tax benefit at the applicable tax rate of 25% (2021: 26%)	3,725,977	2,956,928	1,291,850
Non-deductible expenses	(564,872)	(1,192,112)	(155,498)
Non-assessable income	195,596
Deferred tax assets not recognized	(3,356,701)	(1,764,816)	(1,136,352)
Income tax benefit
Unrecognized Deferred Tax Asset
Unused tax losses	24,845,264	20,867,835
Net unrecognized tax benefit at 25% (2021: 26%)	$ 6,211,316	$ 5,425,637	$ 3,872,022

Income tax (Details) - Schedule of income tax benefit on pre-tax accounting loss from operations reconciles to the inco (Parentheticals)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Income Tax Benefit On Pre Tax Accounting Loss From Operations Reconciles To The Inco Abstract
tax rate	25.00%	26.00%	27.50%
Tax benefit percentage	25.00%	26.00%

Loss per share (Details) - Schedule of loss per share - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Loss Per Share Abstract
Basic loss per share - cents per share	$ (1.25)	$ (1.16)	$ (0.69)
The loss and weighted average number of ordinary shares used in the calculation of basic loss per share is as follows:
Total comprehensive loss for the year	$ (14,903,909)	$ (11,372,799)	$ (4,697,636)
- Weighted average number of ordinary shares (number)	1,191,154,011	976,931,338	684,035,399

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

Dividends (Details)	Jun. 30, 2021 USD ($)
Dividends [Abstract]
Dividend

Cash and Cash Equivalents (Details) - USD ($)	12 Months Ended
Cash and Cash Equivalents (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Schedule of cash and cash equivalents [Abstract]
Share-based payment	$ 600,043	$ 565,448
Non-cash transactions	$ 740,666
Options issued (in Shares)	30,164,690
Exercise options series	$ 262,000,000
Other current liabilities		$ 244,403	$ 244,403

Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Cash And Cash Equivalents Abstract
Cash at bank and on hand	$ 37,500,931	$ 9,123,617	$ 3,603,390
Total	37,500,931	9,123,617	3,603,390
Reconciliation of loss for the year to net cash flows from operating activities:
Loss after income tax	(14,903,909)	(11,372,799)	(4,697,636)
Non-cash based expenses:
Share-based payments	1,464,550	600,043	565,448
Depreciation and amortisation			36,542
Non-cash expense for investor relation services		3,781,344
Release of Gameday reserve of sales refund		(15,484)
Other non-cash expenses	(594,394)	91,354	97,221
Changes in net assets and liabilities:
(Increase)/Decrease in receivables	(92,320)	214,903	(315,484)
(Increase)/Decrease in inventory		183,159	(30,355)
Decrease in other current assets	53,447	172	2,928
Increase/(Decrease) in trade payables and accrued expenses	1,111,080	(291,311)	464,223
Increase/(Decrease) in other liabilities	154,173	(101,161)	(30,221)
Cash flows used in operations	$ (12,807,373)	$ (6,909,780)	$ (3,907,334)

Trade and Other Receivables (Current) (Details) - Schedule of trade and other receivables (Current) - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Trade And Other Receivables Current Abstract
Other receivables		$ 53,447	$ 51,026
GST recoverable	294,717	115,641	137,117
Total trade and other receivables (Current)	$ 294,717	$ 169,088	$ 413,268

Other Assets (current) (Details) - Schedule of other assets (current) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Other Assets Current Abstract
Prepayments	$ 45,911	$ 29,784	$ 11,083
Office rental bond	24,124		25,179
Prepayment clinical trial insurance	13,925	6,306
Other assets (current)	$ 83,960	$ 36,090	$ 36,262

Trade and Other Payables (Current) (Details) - Schedule of trade and other payables (Current) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Trade And Other Payables Current Abstract
Trade payables	$ 1,300,696	$ 233,117	$ 590,099
Accrued expenses	415,449	381,717	316,046
Employee leave entitlements	294,388	140,215	48,861
Total	$ 2,010,533	$ 755,049	$ 955,006

Issued Capital (Details)	12 Months Ended
Issued Capital (Details)	Jun. 30, 2022	Jun. 30, 2021
Schedule of issued capital [Abstract]
Shareholder vote	one	one

Issued Capital (Details) - Schedule of issued capital - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Issued Capital Abstract
Ordinary shares	$ 86,586,794	$ 45,852,107	$ 34,192,043

Issued Capital (Details) - Schedule of ordinary shares movements during years - USD ($)

12 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2020

At start of year

$ 45,852,107

Number of shares, At start of year

1,068,411,224

748,654,489

581,897,040

Issues of new shares – placements

$ 400,000

Number of shares, Issues of new shares – placements

5,000,000

114,663,460

Issues of new shares – share based payments1

^[1]

Number of shares, Issues of new shares – share based payments1

^[1]

10,000,000

Exercise of options

$ 40,274,243

Number of shares, Exercise of options

207,650,638

286,500,523

34,427,321

Shares in lieu of advisor fees

$ 450,000

Number of shares, Shares in lieu of advisor fees

1,272,166

Share issue costs

$ (389,555)

Number of shares, Share issue costs

At end of year

$ 86,586,794

$ 45,852,107

Number of shares, At end of year

1,292,334,028

1,068,411,224

748,654,489

[1]

Reserves (Details) - $ / shares		12 Months Ended
Reserves (Details) - $ / shares	Aug. 09, 2019	Jun. 30, 2021	Jun. 30, 2020
Reserves (Details) [Line Items]
Options exercisable shares (in Shares)	120,000,000	40,000,000	33,000,000
Investor issued per share		$ 0.08	$ 0.08
Share price	$ 0.02		$ 0.04
Risk-free percentage	1.07%		0.24%
Volatility percentage	59.00%		92.00%
Investors [Member]
Reserves (Details) [Line Items]
Investor issued per share		0.15
Investor one [Member]
Reserves (Details) [Line Items]
Investor issued per share		0.2
Investor two [Member]
Reserves (Details) [Line Items]
Investor issued per share		$ 25
In addition [Member]
Reserves (Details) [Line Items]
Options exercisable shares (in Shares)		30,164,690

Reserves (Details) - Schedule of equity based premium reserve - USD ($)

12 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2020

Schedule Of Equity Based Premium Reserve Abstract

Balance beginning

$ 6,612,641

$ 1,490,588

$ 451,643

Options issued to advisors

^[1]

4,522,010

^[1],[2]

449,093

^[2]

Equity instruments issued to management and directors

1,464,550

600,043

Balance ending

$ 8,077,191

$ 6,612,641

$ 1,490,588

[1]

[2]

During the year ended 30 June 2021, 40,000,000 options exercisable at $0.15, $0.20, and $.25 were issued to consultants for investor relation services. In addition, 30,164,690 options exercisable at $0.08 were issued as consideration for broker support of the exercise of the 262m listed IHLOB options series (see Note 12). During the year ended 30 June 2020, 33,000,000 options exercisable at $0.08 and expiring on 30 September 2021, were issued to brokers who supported the July 2019 capital raisings. These options have been valued using a Black-Scholes option model with inputs being grant date share price of $0.04 risk-free rate of 0.24% and volatility of 92%.

Share Based Payments (Details) - USD ($)	1 Months Ended	12 Months Ended
Share Based Payments (Details) - USD ($)	Jun. 26, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Share Based Payments (Details) [Line Items]
Total value (in Dollars)		$ 3,588,000		$ 469,324
Unrecognized compensation cost (in Dollars)		$ 2,743,854	$ 116,680
Exercise price of options outstanding		$ 0.08	$ 0.35
Weighted-average period term		1 year 4 months 20 days	1 year
Performance rights converted into ordinary share (in Shares)		30,303,593	30,303,593	11,916,668
Performance rights expired (in Shares)		11,250,000	11,250,000	3,000,000
Fair value of options granted			$ 0.1	$ 0.22
Equity capital raisings, description			(1)22,368,422 options were issued to participants of the July 2019 equity capital raisings attaching to shares subscribed for under those raisings and 33,000,000 options were issued to brokers who supported those equity capital raisings. A further 34,551,283 options were issued to participants of the October 2019 capital raising attaching to shares subscribed for under that raising.
Options, description			(a)The options vest upon the shares having a closing price of 20 cents per share or more for any 5 trading days at any time from the date of grant of the options until the expiry date of the options (30 September 2021).
Performance rights were issued (in Shares)	32,303,593
Grant date share price (in Shares)				0.048
Risk-free rate				0.25%
Volatility percentage				95.00%
Performance rights (in Dollars)			$ 280,253	$ 189,071
Performance rights share price			$ (0.048)
Options [Member]
Share Based Payments (Details) [Line Items]
Exercise price of options outstanding			$ 0.05	$ 0.25
Option contract [member]
Share Based Payments (Details) [Line Items]
Unrecognized compensation cost (in Dollars)		$ 1,853,263
Black-Scholes Options Model [Member]
Share Based Payments (Details) [Line Items]
Fair value of the equity-settled share options				0.05
Trinomial Option Model [Member]
Share Based Payments (Details) [Line Items]
Fair value of the equity-settled share options				$ 0.2

Share Based Payments (Details) - Schedule of share options were issued to employees and consultants as share based payments - Options [Member] - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Options granted to employees
Total options	10,000,000	70,164,690
Total options	$ 2,371,867	$ 4,521,507
Unlisted options [Member] \| Options granted to Directors [Member]
Options granted to Directors
Number of options granted to Directors	1,399,999
Grant date of options granted to Directors	Jun. 09, 2022
Expiry date of options granted to Directors	Jul. 01, 2025
Exercise price of options granted to Directors	$ 0.26
Total fair value of options granted to Directors	$ 298,200
Unlisted options [Member] \| Options granted to employees [Member]
Options granted to employees
Number of options granted to employees	533,333
Grant date of uoptions granted to employees	Apr. 29, 2022
Expiry date of options granted to employees	Jul. 01, 2025
Exercise price of options granted to employees	$ 0.26
Total fair value of options granted to employees	$ 139,200
Unlisted options [Member] \| Options granted to third parties [Member]
Options granted to third parties
Number of options granted to third parties		10,000,000
Grant date of options granted to third parties		Nov. 20, 2020
Expiry date of options granted to third parties		Nov. 20, 2023
Exercise price of options granted to third parties		$ 0.15
Total fair value of options granted to third parties		$ 647,348
Unlisted options One [Member] \| Options granted to Directors [Member]
Options granted to Directors
Number of options granted to Directors	1,399,999
Grant date of options granted to Directors	Jun. 09, 2022
Expiry date of options granted to Directors	Jul. 01, 2026
Exercise price of options granted to Directors	$ 0.31
Total fair value of options granted to Directors	$ 309,400
Unlisted options One [Member] \| Options granted to employees [Member]
Options granted to employees
Number of options granted to employees	533,333
Grant date of uoptions granted to employees	Apr. 29, 2022
Expiry date of options granted to employees	Jul. 01, 2026
Exercise price of options granted to employees	$ 0.31
Total fair value of options granted to employees	$ 143,467
Unlisted options One [Member] \| Options granted to third parties [Member]
Options granted to third parties
Number of options granted to third parties		10,000,000
Grant date of options granted to third parties		Nov. 20, 2020
Expiry date of options granted to third parties		Nov. 20, 2023
Exercise price of options granted to third parties		$ 0.25
Total fair value of options granted to third parties		$ 527,766
Unlisted options Two [Member] \| Options granted to Directors [Member]
Options granted to Directors
Number of options granted to Directors	1,400,002
Grant date of options granted to Directors	Jun. 09, 2022
Expiry date of options granted to Directors	Jul. 01, 2027
Exercise price of options granted to Directors	$ 0.35
Total fair value of options granted to Directors	$ 324,800
Unlisted options Two [Member] \| Options granted to employees [Member]
Options granted to employees
Number of options granted to employees	533,334
Grant date of uoptions granted to employees	Apr. 29, 2022
Expiry date of options granted to employees	Jul. 01, 2027
Exercise price of options granted to employees	$ 0.35
Total fair value of options granted to employees	$ 148,800
Unlisted options Two [Member] \| Options granted to third parties [Member]
Options granted to third parties
Number of options granted to third parties		10,000,000
Grant date of options granted to third parties		Feb. 25, 2021
Expiry date of options granted to third parties		Nov. 20, 2023
Exercise price of options granted to third parties		$ 0.2
Total fair value of options granted to third parties		$ 1,352,588
Unlisted options Three [Member] \| Options granted to Directors [Member]
Options granted to Directors
Number of options granted to Directors	1,399,999
Grant date of options granted to Directors	Jun. 09, 2022
Expiry date of options granted to Directors	Jul. 01, 2026
Exercise price of options granted to Directors	$ 0.26
Total fair value of options granted to Directors	$ 326,200
Unlisted options Three [Member] \| Options granted to third parties [Member]
Options granted to third parties
Number of options granted to third parties		10,000,000
Grant date of options granted to third parties		Feb. 25, 2021
Expiry date of options granted to third parties		Nov. 20, 2023
Exercise price of options granted to third parties		$ 0.25
Total fair value of options granted to third parties		$ 1,253,140
Unlisted options Four [Member] \| Options granted to Directors [Member]
Options granted to Directors
Number of options granted to Directors	1,399,999
Grant date of options granted to Directors	Jun. 09, 2022
Expiry date of options granted to Directors	Jul. 01, 2027
Exercise price of options granted to Directors	$ 0.31
Total fair value of options granted to Directors	$ 334,600
Unlisted options Four [Member] \| Options granted to third parties [Member]
Options granted to third parties
Number of options granted to third parties		30,164,690
Grant date of options granted to third parties		Oct. 02, 2020
Expiry date of options granted to third parties		Sep. 30, 2021
Exercise price of options granted to third parties		$ 0.08
Total fair value of options granted to third parties		$ 740,665
Unlisted options Five [Member] \| Options granted to Directors [Member]
Options granted to Directors
Number of options granted to Directors	1,400,002
Grant date of options granted to Directors	Jun. 09, 2022
Expiry date of options granted to Directors	Jul. 01, 2028
Exercise price of options granted to Directors	$ 0.35
Total fair value of options granted to Directors	$ 347,200

Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes - $ / shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
$0.26 Options 01-Jul-25 [member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number	1,399,999
Expected volatility (%)	80.00%
Risk-free interest rate (%)	3.12%
Expected life of option (years)	3 years 21 days
Exercise price (cents)	$ 26
Grant date share price (cents)	$ 35
Vesting date	30-Jun-22
$0.31 Options 01-Jul-26 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number	1,399,999
Expected volatility (%)	80.00%
Risk-free interest rate (%)	3.33%
Expected life of option (years)	4 years 21 days
Exercise price (cents)	$ 31
Grant date share price (cents)	$ 35
Vesting date	30-Jun-23
$0.35 Options 01-Jul-27 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number	1,400,002
Expected volatility (%)	80.00%
Risk-free interest rate (%)	3.33%
Expected life of option (years)	5 years 21 days
Exercise price (cents)	$ 35
Grant date share price (cents)	$ 35
Vesting date	30-Jun-24
$0.26 Options 01-Jul-26 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number	1,399,999
Expected volatility (%)	80.00%
Risk-free interest rate (%)	3.33%
Expected life of option (years)	4 years 21 days
Exercise price (cents)	$ 26
Grant date share price (cents)	$ 35
Vesting date	30-Jun-23
$0.31 Options 01-Jul-27 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number	1,399,999
Expected volatility (%)	80.00%
Risk-free interest rate (%)	3.33%
Expected life of option (years)	5 years 21 days
Exercise price (cents)	$ 31
Grant date share price (cents)	$ 35
Vesting date	30-Jun-24
$0.35 Options 01-Jul-28 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number	1,400,002
Expected volatility (%)	80.00%
Risk-free interest rate (%)	3.33%
Expected life of option (years)	6 years 25 days
Exercise price (cents)	$ 35
Grant date share price (cents)	$ 35
Vesting date	30-Jun-25
$0.26 Options 01-Jul-25 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number	533,333
Expected volatility (%)	80.00%
Risk-free interest rate (%)	2.71%
Expected life of option (years)	3 years 2 months 4 days
Exercise price (cents)	$ 26
Grant date share price (cents)	$ 41
Vesting date	01-Jul-22
$0.31 Options 01-Jul-26 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number	533,333
Expected volatility (%)	80.00%
Risk-free interest rate (%)	2.90%
Expected life of option (years)	4 years 2 months 4 days
Exercise price (cents)	$ 31
Grant date share price (cents)	$ 41
Vesting date	01-Jul-23
$0.35 Options 01-Jul-27 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number	533,334
Expected volatility (%)	80.00%
Risk-free interest rate (%)	2.90%
Expected life of option (years)	5 years 2 months 4 days
Exercise price (cents)	$ 35
Grant date share price (cents)	$ 41
Vesting date	01-Jul-24
$0.08 Options 30-Sep-21 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number		30,164,690
Expected volatility (%)		100.00%
Risk-free interest rate (%)		0.17%
Expected life of option (years)		1 year
Exercise price (cents)		$ 8
Grant date share price (cents)		$ 7.7
Vesting date		2-Oct-20
$0.15 Options 20-Nov-23 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number		10,000,000
Expected volatility (%)		100.00%
Risk-free interest rate (%)		0.11%
Expected life of option (years)		3 years
Exercise price (cents)		$ 15
Grant date share price (cents)		$ 11.5
Vesting date		20-Nov-20
$0.25 Options 20-Nov-23 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number		10,000,000
Expected volatility (%)		100.00%
Risk-free interest rate (%)		0.11%
Expected life of option (years)		3 years
Exercise price (cents)		$ 25
Grant date share price (cents)		$ 11.5
Vesting date		20-Nov-20
$0.20 Options 20-Nov-23 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number		10,000,000
Expected volatility (%)		101.00%
Risk-free interest rate (%)		0.12%
Expected life of option (years)		2 years 8 months 12 days
Exercise price (cents)		$ 20
Grant date share price (cents)		$ 22
Vesting date		25-Feb-21
$0.25 Options 20-Nov-23 [Member]
Share Based Payments (Details) - Schedule of equity-settled share options granted is estimated as at the grant date Black-Scholes [Line Items]
Number		10,000,000
Expected volatility (%)		101.00%
Risk-free interest rate (%)		0.12%
Expected life of option (years)		2 years 8 months 12 days
Exercise price (cents)		$ 25
Grant date share price (cents)		$ 22
Vesting date		25-Feb-21

Share Based Payments (Details) - Schedule of number of performance shares and performance rights - shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Number Of Performance Shares And Performance Rights Abstract
$0.$0.08 Options	30-Sep-21	30-Sep-21
Balance at start of year		41,553,593
Granted by the Company
Converted or Expired		(41,553,593)
Balance at end of year

Remuneration of Auditors (Details) - Schedule of remuneration of auditors - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Audit or review of the financial reports of the company
Audit services – PKF Brisbane Audit	$ 85,000
Audit services – HLB Mann Judd	23,138	37,785	$ 37,000
Audit services – Withum Smith & Brown (US auditor)	357,208	287,975
Other services – Withum Smith & Brown (US auditor)
Total	$ 465,346	$ 325,760	$ 37,000

Financial Instruments (Details) - Schedule of contractual liabilities - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Financial Instruments (Details) - Schedule of contractual liabilities [Line Items]
Payables & accruals	$ 1,828,527	$ 614,834	$ 906,145
Total payables	1,828,527	614,834	906,145
Less than 1 month [Member]
Financial Instruments (Details) - Schedule of contractual liabilities [Line Items]
Payables & accruals	1,828,527	614,834	906,145
Total payables	1,828,527	614,834	906,145
1 to 3 months [Member]
Financial Instruments (Details) - Schedule of contractual liabilities [Line Items]
Payables & accruals
Total payables
3 months to 1 year [Member]
Financial Instruments (Details) - Schedule of contractual liabilities [Line Items]
Payables & accruals
Total payables
1 to 5 years [Member]
Financial Instruments (Details) - Schedule of contractual liabilities [Line Items]
Payables & accruals
Total payables

Commitments and Contingencies (Details)	12 Months Ended
Commitments and Contingencies (Details)	Jun. 30, 2022
Disclosure of Commitments and Contingent Liabilities Text Block Abstract
Commencement of agreement percentage	50.00%

Key Management Personnel Compensation and Related Party Disclosure (Details) - USD ($)		12 Months Ended
	Aug. 09, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule of key management personnel compensation [Abstract]
Fees paid		$ 407,824	$ 97,976	$ 145,200
Reversal of expense			$ 72,656
Share options issued (in Shares)	120,000,000		88,000,000
Total revenues, percentage				100.00%
Amounts payable to related parties			$ 229,889

Key Management Personnel Compensation and Related Party Disclosure (Details) - Schedule of key management personnel compensation - USD ($)

12 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2020

Schedule Of Key Management Personnel Compensation Abstract

Short-term employee benefits

$ 1,333,992

$ 761,231

$ 638,201

Post-employment benefits

47,547

38,877

29,985

Share based payments

1,028,634

672,699

^[1]

565,448

^[1]

Total KMP compensation

$ 2,410,173

$ 1,472,807

$ 1,233,634

[1]

Details of the Controlled Entity (Details) - shares	12 Months Ended
Details of the Controlled Entity (Details) - shares	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Incannex Pty Ltd [Member]
Details of the Controlled Entity (Details) [Line Items]
Increase (decrease) in number of ordinary shares issued (in Shares)	1
Subsidiary		100.00%
Ordinary shares			100.00%
Psychennex Pty Ltd [Member]
Details of the Controlled Entity (Details) [Line Items]
Subsidiary	100.00%	100.00%
Incannex Healthcare Limited [Member]
Details of the Controlled Entity (Details) [Line Items]
Ordinary shares		100.00%
Gameday International Pty Ltd [Member]
Details of the Controlled Entity (Details) [Line Items]
Subsidiary			100.00%

Events Subsequent to Reporting Date (Details) - USD ($)	Aug. 05, 2022	Oct. 07, 2021	Oct. 04, 2021	Sep. 21, 2021	Sep. 07, 2021	Aug. 25, 2021	Aug. 16, 2021	Jul. 21, 2021
Disclosure Of Events After Reporting Period Text Block Abstract
Issued capital	218,169,497
Issued ordinary shares		6,852,322	11,427,616	61,311,557	7,345,833	9,201,186		239,103
Exercise price per share (in Dollars per share)		$ 0.08	$ 0.08	$ 0.08	$ 0.08	$ 0.08	$ 0.08	$ 0.08
Receiving of proceeds (in Dollars)								$ 19,128
Additional ordinary shares							2,739,662
Proceeds amount (in Dollars)		$ 548,186		$ 4,904,925		$ 736,095	$ 219,173
Total proceeds (in Dollars)			$ 5,114,109		$ 4,587,667
Issued ordinary shares			20,999,500		20,000,000
Exercise price per share (in Dollars per share)			$ 0.2		$ 0.2

Parent Entity Disclosures (Details)	Jun. 30, 2021 USD ($)
Parent Entity Disclosures Abstract
Contingent liabilities
Guarantees involving

Parent Entity Disclosures (Details) - Schedule of statement of financial position - Parent [member] - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Condensed Financial Statements, Captions [Line Items]
Current assets	$ 37,559,819	$ 9,222,528
Non-Current assets
Total assets	37,559,819	9,222,528
Current liabilities	(1,078,404)	(668,527)
Non-current liabilities
Total liabilities	(1,078,404)	(668,527)
Net assets	36,481,415	8,554,001
Issued capital	86,586,794	45,852,107
Reserves	8,077,191	6,612,641
Accumulated losses	(58,182,570)	(43,910,747)
Shareholders’ equity	$ 36,481,415	$ 8,554,001

Significant Accounting Policies (Details) - Schedule of straight-line basis to write off the net cost of each item of property, plant, and equipment	12 Months Ended
	Jun. 30, 2021
Buildings [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis to write off the net cost of each item of property, plant, and equipment [Line Items]
Property plant and equipment useful lives	40 years
Leasehold improvements [Member] \| Minimum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis to write off the net cost of each item of property, plant, and equipment [Line Items]
Property plant and equipment useful lives	3 years
Leasehold improvements [Member] \| Maximum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis to write off the net cost of each item of property, plant, and equipment [Line Items]
Property plant and equipment useful lives	10 years
Plant and equipment [Member] \| Minimum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis to write off the net cost of each item of property, plant, and equipment [Line Items]
Property plant and equipment useful lives	3 years
Plant and equipment [Member] \| Maximum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis to write off the net cost of each item of property, plant, and equipment [Line Items]
Property plant and equipment useful lives	7 years

Revenue & expenses (Details) - Schedule of revenue & expenses - USD ($)

12 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2020

Schedule Of Revenue Expenses Abstract

Cannabinoid oils sales

$ 1,897,596

$ 604,884

Total revenue

1,897,596

604,884

Income from other arrangements

35,569

^[1]

123,125

^[1]

Government grants

37,500

^[2]

89,500

^[2]

Interest

6,271

2,679

4,545

Total other income

$ 788,654

75,748

217,170

Executive directors’ remuneration

$ 600,043

$ 539,923

[1]

[2]

Segment Information (Details) - Schedule of segment results - USD ($)

12 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2020

Oral and Dental Devices [Member]

Segment Information (Details) - Schedule of segment results [Line Items]

$ 718,656

140,816

(14,854)

(21,688)

(1,591,290)

(768,352)

Segment Information (Details) - Schedule of segment results [Line Items]

Psychedelic [Member]

(883,708)

(768,316)

(883,708)

(768,316)

$ 56,058

2,000

Medicinal Cannabis [Member]

Segment Information (Details) - Schedule of segment results [Line Items]

^[1]

1,897,596

604,884

212,625

(5,202,371)

(2,899,761)

(3,304,769)

(2,082,250)

104,267

662,414

Segment Information (Details) - Schedule of segment results [Line Items]

(86,522)

(567,423)

Unallocated [Member]

Interest income

2,673

4,543

73,069

(7,375,456)

(1,851,577)

(7,299,714)

(1,847,034)

9,222,528

3,573,665

Segment Information (Details) - Schedule of segment results [Line Items]

(668,527)

(504,228)

Consolidated [Member]

1,897,596

1,323,540

Interest income

2,679

4,553

Other income

73,069

353,441

Depreciation

(14,854)

Amortisation

(21,688)

(13,346,143)

(6,342,628)

(11,372,799)

(4,697,636)

9,328,795

4,236,079

$0.08 Options 30-Sep-2021 [Member]

$ (755,049)

$ (1,071,651)

[1]	Of the total revenue from medicinal cannabis in the fiscal year ended 30 June 2021 and 2020, 100% was through Cannvalate Pty Ltd’s distribution network.

Income tax (Details) - Schedule of the prima facie income tax (expense)/benefit on pre-tax accounting (loss)/profit from operations reconcile - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of The Prima Facie Income Tax Expense Benefit On Pre Tax Accounting Loss Profit From Operations Reconcile Abstract
Accounting loss before tax	$ (14,903,909)	$ (11,372,799)	$ (4,697,636)
Income tax benefit at the applicable tax rate of 26% (2020: 27.5%)	3,725,977	2,956,928	1,291,850
Non-deductible expenses at the applicable tax rate of 26% (2020:27.5%)	(564,872)	(1,192,112)	(155,498)
Deferred tax assets not recognised	(3,356,701)	(1,764,816)	(1,136,352)
Income tax benefit
Deductible temporary differences for which no deferred tax asset has been recognized
Unused tax losses at 26% (2020: 27.5%)		5,425,637	3,872,022
Net unrecognized tax benefit	$ 6,211,316	$ 5,425,637	$ 3,872,022

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

Income tax (Details) - Schedule of the prima facie income tax (expense)/benefit on pre-tax accounting (loss)/profit from operations reconcile (Parentheticals)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of The Prima Facie Income Tax Expense Benefit On Pre Tax Accounting Loss Profit From Operations Reconcile Abstract
Tax rate	25.00%	26.00%	27.50%
Non-deductible tax rate		26.00%	27.50%
Unused tax losses percentage		26.00%	27.50%

Discontinued operations (Details)	Jun. 30, 2020 USD ($)
Disclosure Of Non Current Assets Held For Sale And Discontinued Operations Text Block Abstract
Consolidated entity sold percentage	100.00%
Carrying value of assets	$ 29,277

Discontinued operations (Details) - Schedule of financial performance information - Financial Performance Information [Member] - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Discontinued operations (Details) - Schedule of financial performance information [Line Items]
Revenue from external customers		$ 718,656
Interest income		8
Other income		140,816
Product costs		(589,570)
Administration expense		(38,985)
Advertising and promotion		(218,865)
Depreciation		(14,854)
Amortisation		(21,688)
Loss on disposal of property, plant and equipment		(13,654)
Impairment cost		(82,989)
Occupancy expenses		(81,493)
Salaries and employee benefit expense		(565,734)
Loss before income tax		(768,352)
Income tax benefit
Loss after income tax from discontinued operations		(768,352)
Cash		17,970
Inventories		6,000
Other current assets		6,100
Trade and other payables		(793)
Total proceeds from sale		$ 29,277

Discontinued operations (Details) - Schedule of plant and equipment	12 Months Ended
	Jun. 30, 2020 USD ($)
Discontinued operations (Details) - Schedule of plant and equipment [Line Items]
Book value prior to impairment	$ 82,989
Plant and Equipment [Member]
Discontinued operations (Details) - Schedule of plant and equipment [Line Items]
Original Cost	76,136
Accumulated Depreciation	(32,221)
Book value prior to impairment	43,915
Receivables [Member]
Discontinued operations (Details) - Schedule of plant and equipment [Line Items]
Book value prior to impairment	11,385
Original book value	11,635
Recoverable amount	(250)
Intangible Assets [Member]
Discontinued operations (Details) - Schedule of plant and equipment [Line Items]
Original Cost	116,731
Accumulated Depreciation	(89,042)
Book value prior to impairment	$ 27,689

Loss Per Share (Details) - Schedule of loss per share - $ / shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Loss Per Share Abstract
Basic loss per share– continuing and discontinued operations – cents per share	$ (1.25)	$ (1.16)	$ (0.69)
Basic loss per share– continuing operations – cents per share		(1.16)	(0.57)
The loss and weighted average number of ordinary shares used in the calculation of basic loss per share is as follows:
Loss from continuing and discontinued operations		(11,372,799)	(4,697,636)
Loss from continuing operations		$ (11,372,799)	$ (3,929,284)
Weighted average number of ordinary shares (number) (in Shares)	1,191,154,011	976,931,338	684,035,399

Cash (Details) - Schedule of cash - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Cash Abstract
Cash at bank and on hand	$ 37,500,931	$ 9,123,617	$ 3,603,390
Total	$ 37,500,931	$ 9,123,617	$ 3,603,390

Cash (Details) - Schedule of net cash flows from operating activities - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Net Cash Flows From Operating Activities Abstract
Loss after income tax	$ (14,903,909)	$ (11,372,799)	$ (4,697,636)
Non-cash based expenses(income):
Share based payments	1,464,550	600,043	565,448
Depreciation and amortisation			36,542
Non-cash expense for investor relation services		3,781,344
Release of Gameday reserve of sales refund		(15,484)
Non-cash expense for annual leave	(594,394)	91,354	97,221
Changes in net assets and liabilities:
Decrease/(increase) in receivables	(92,320)	214,903	(315,484)
Decrease/(increase) in inventory		183,159	(30,355)
Decrease in other current assets	53,447	172	2,928
(Increase)/decrease in trade and other payables	1,111,080	(291,311)	464,223
Decrease in other liabilities	154,173	(101,161)	(30,221)
Cash flows used in operations	$ (12,807,373)	$ (6,909,780)	$ (3,907,334)

Trade and Other Receivables (Current) (Details) - Schedule of trade and other receivables (Current) - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Current
Trade receivables			$ 225,125
Other receivables		53,447	51,026
GST recoverable	294,717	115,641	137,117
Total trade and other receivables (Current)	$ 294,717	$ 169,088	$ 413,268

Other assets (current) (Details) - Schedule of other assets (current) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Other Assets Current Abstract
Prepayments	$ 45,911	$ 29,784	$ 11,083
Office rental bond	24,124		25,179
Prepayment clinical trial insurance	13,925	6,306
Other assets (current)	$ 83,960	$ 36,090	$ 36,262

Share Based Payments (Details) - Schedule of table summarizes company’s stock option activity	12 Months Ended
	Jun. 30, 2021 $ / shares	Jun. 30, 2020 $ / shares
Schedule Of Table Summarizes Company SStock Option Activity Abstract
Number of Options Outstanding beginning	640,703,112	262,960,728
Weighted Average Exercise Price Outstanding beginning	$ 0.104	$ 0.04
Weighted Average Remaining Contractual Life (years) Outstanding beginning		1 year 3 months 1 day
Number of Options Granted	72,414,690	412,169,705
Weighted Average Exercise Price Granted	$ 0.152	$ 0.139
Number of Options Exercised	(286,500,523)	(34,427,321)
Weighted Average Exercise Price Exercised	$ 0.044	$ 0.031
Number of Options Expired or forfeited	(88,000,000)
Weighted Average Exercise Price Expired or forfeited	$ 0.104
Number of Options Outstanding ending	338,617,279	640,703,112
Weighted Average Exercise Price Outstanding ending	$ 0.166	$ 0.104
Weighted Average Remaining Contractual Life (years) Outstanding ending	6 months 24 days	8 months 29 days
Number of Options Exercisable as of 30 June 2021	337,117,279
Weighted Average Exercise Price Exercisable as of 30 June 2021	$ 0.167

Share Based Payments (Details) - Schedule of consultants as share based payments - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2022
Options granted to third parties
Number Total options granted to third parties	70,164,690	209,919,705
Exercise Price Total options granted to third parties	$ 0.35		$ 0.08
Total fair value Total options granted to third parties	$ 4,521,507	$ 693,470
Options granted to employees
Number Total options granted to employees	2,250,000	202,250,000
Total fair value Total options granted to employees	$ 81,922	$ 385,294
Total options	72,414,690	412,169,705
Total options	$ 4,603,429	$ 1,078,764
Option Granted To Third Parties [Member] \| Unlisted Option [Member]
Options granted to third parties
Number Total options granted to third parties	10,000,000
Grant Date Total options granted to third parties	Nov. 20, 2020
Expiry Date Total options granted to third parties	Nov. 20, 2023
Exercise Price Total options granted to third parties	$ 0.15
Total fair value Total options granted to third parties	$ 647,348
Option Granted To Third Parties [Member] \| Unlisted options One [Member]
Options granted to third parties
Number Total options granted to third parties	10,000,000	10,000,000
Grant Date Total options granted to third parties	Nov. 20, 2020	Aug. 08, 2019
Expiry Date Total options granted to third parties	Nov. 20, 2023	May 01, 2020
Exercise Price Total options granted to third parties	$ 0.25	$ 0.03
Total fair value Total options granted to third parties	$ 527,766	$ 51,531
Options granted to employees
Number Total options granted to employees	750,000	750,000
Grant Date Total options granted to employees	Jul. 01, 2020	Jun. 26, 2020
Expiry Date Total options granted to employees	Jun. 30, 2026	Jun. 30, 2026
Exercise Price Total options granted to employees	$ 0.05	$ 0.05
Total fair value Total options granted to employees	$ 27,450	$ 26,424
Option Granted To Third Parties [Member] \| Unlisted options Two [Member]
Options granted to third parties
Number Total options granted to third parties	10,000,000	12,000,000
Grant Date Total options granted to third parties	Feb. 25, 2021	Aug. 08, 2019
Expiry Date Total options granted to third parties	Nov. 20, 2023	May 01, 2020
Exercise Price Total options granted to third parties	$ 0.2	$ 0.04
Total fair value Total options granted to third parties	$ 1,352,588	$ 34,966
Options granted to employees
Number Total options granted to employees	750,000	750,000
Grant Date Total options granted to employees	Jul. 01, 2020	Jun. 26, 2020
Expiry Date Total options granted to employees	Jun. 30, 2027	Jun. 30, 2027
Exercise Price Total options granted to employees	$ 0.05	$ 0.05
Total fair value Total options granted to employees	$ 29,040	$ 27,754
Option Granted To Third Parties [Member] \| Unlisted options Three [Member]
Options granted to third parties
Number Total options granted to third parties	10,000,000	14,000,000
Grant Date Total options granted to third parties	Feb. 25, 2021	Aug. 19, 2019
Expiry Date Total options granted to third parties	Nov. 20, 2023	Dec. 01, 2020
Exercise Price Total options granted to third parties	$ 0.25	$ 0.06
Total fair value Total options granted to third parties	$ 1,253,140	$ 30,297
Options granted to employees
Number Total options granted to employees		200,000,000
Grant Date Total options granted to employees		Jun. 26, 2020
Expiry Date Total options granted to employees		Sep. 30, 2021
Exercise Price Total options granted to employees		$ 0.2
Total fair value Total options granted to employees		$ 306,299
Option Granted To Third Parties [Member] \| Unlisted options Four [Member]
Options granted to third parties
Number Total options granted to third parties	30,164,690	16,000,000
Grant Date Total options granted to third parties	Oct. 02, 2020	Aug. 19, 2019
Expiry Date Total options granted to third parties	Sep. 30, 2021	Dec. 01, 2020
Exercise Price Total options granted to third parties	$ 0.08	$ 0.08
Total fair value Total options granted to third parties	$ 740,665	$ 18,248
Option Granted To Third Parties [Member] \| Unlisted options [Member]
Options granted to third parties
Number Total options granted to third parties		10,000,000
Grant Date Total options granted to third parties		Aug. 08, 2019
Expiry Date Total options granted to third parties		Jan. 01, 2020
Exercise Price Total options granted to third parties		$ 0.02
Total fair value Total options granted to third parties		$ 85,251
Options granted to employees
Number Total options granted to employees	750,000	750,000
Grant Date Total options granted to employees	Jul. 01, 2020	Jun. 26, 2020
Expiry Date Total options granted to employees	Jun. 30, 2025	Jun. 30, 2025
Exercise Price Total options granted to employees	$ 0.05	$ 0.05
Total fair value Total options granted to employees	$ 25,432	$ 24,817
Option Granted To Third Parties [Member] \| Unlisted options Five [Member]
Options granted to third parties
Number Total options granted to third parties		18,000,000
Grant Date Total options granted to third parties		Aug. 19, 2019
Expiry Date Total options granted to third parties		Dec. 01, 2020
Exercise Price Total options granted to third parties		$ 0.1
Total fair value Total options granted to third parties		$ 11,606
Option Granted To Third Parties [Member] \| Unlisted options Six [Member]
Options granted to third parties
Number Total options granted to third parties		20,000,000
Grant Date Total options granted to third parties		Aug. 19, 2019
Expiry Date Total options granted to third parties		Dec. 01, 2020
Exercise Price Total options granted to third parties		$ 0.12
Total fair value Total options granted to third parties		$ 7,700
Option Granted To Third Parties [Member] \| Unlisted options Seven [Member]
Options granted to third parties
Number Total options granted to third parties		20,000,000
Grant Date Total options granted to third parties		Aug. 19, 2019
Expiry Date Total options granted to third parties		Dec. 01, 2020
Exercise Price Total options granted to third parties		$ 0.14
Total fair value Total options granted to third parties		$ 4,804
Option Granted To Third Parties [Member] \| Unlisted options Eight [Member]
Options granted to third parties
Number Total options granted to third parties		89,919,705
Expiry Date Total options granted to third parties		Sep. 30, 2021
Exercise Price Total options granted to third parties		$ 0.08
Total fair value Total options granted to third parties		$ 449,067

Share Based Payments (Details) - Schedule of share options granted is estimated the grant date Black-Scholes - $ / shares

12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Share Based Payments (Details) - Schedule of share options granted is estimated the grant date Black-Scholes [Line Items]

30,164,690

86.00%

0.17%

1 year

Grant date share price (cents) (in Dollars per share)

$ 8

$ 7.7

$0.15 Options 20-Nov-2023 [Member]

2-Oct-2020

Share Based Payments (Details) - Schedule of share options granted is estimated the grant date Black-Scholes [Line Items]

10,000,000

100.00%

0.11%

3 years

Grant date share price (cents) (in Dollars per share)

$ 15

$ 11.5

$0.25 Options 20-Nov-2023 [Member]

20-Nov-2020

Share Based Payments (Details) - Schedule of share options granted is estimated the grant date Black-Scholes [Line Items]

10,000,000

100.00%

0.11%

3 years

Grant date share price (cents) (in Dollars per share)

$ 25

$ 11.5

$0.20 Options 20-Nov-2023 [Member]

20-Nov-2020

Share Based Payments (Details) - Schedule of share options granted is estimated the grant date Black-Scholes [Line Items]

10,000,000

101.00%

0.12%

2 years 8 months 12 days

Grant date share price (cents) (in Dollars per share)

$ 20

$ 22

$0.25 Options 20-Nov-2023 One [Member]

25-Feb-2021

Share Based Payments (Details) - Schedule of share options granted is estimated the grant date Black-Scholes [Line Items]

10,000,000

101.00%

0.12%

2 years 8 months 12 days

Grant date share price (cents) (in Dollars per share)

$ 25

$ 22

$0.05 Options 30-Jun-2025 [Member]

25-Feb-2021

Share Based Payments (Details) - Schedule of share options granted is estimated the grant date Black-Scholes [Line Items]

750,000

92.00%

0.39%

5 years

Grant date share price (cents) (in Dollars per share)

$ 5

$ 4.8

$0.05 Options 30-Jun-2026 [Member]

30-Jun-2020

Share Based Payments (Details) - Schedule of share options granted is estimated the grant date Black-Scholes [Line Items]

750,000

92.00%

0.48%

6 years

Grant date share price (cents) (in Dollars per share)

$ 5

$ 4.8

$0.05 Options 30-Jun-2027 [Member]

30-Jun-2021

Share Based Payments (Details) - Schedule of share options granted is estimated the grant date Black-Scholes [Line Items]

750,000

92.00%

0.58%

7 years

Grant date share price (cents) (in Dollars per share)

$ 5

$ 4.8

$0.20 Options 30-Sep-2021 [Member]

30-Jun-2022

Share Based Payments (Details) - Schedule of share options granted is estimated the grant date Black-Scholes [Line Items]

2,000,000

93.00%

0.25%

1 year 3 months

Grant date share price (cents) (in Dollars per share)

$ 20

$ 4.8